AKR1E2 is a cytosolic oxidoreductase belonging to the aldo-keto reductase superfamily, catalyzing NADPH-dependent reduction reactions 1. While its primary substrate appears to be 1,5-anhydro-D-fructose (AF), which it reduces to 1,5-anhydro-D-glucitol, it also demonstrates low reductase activity toward xenobiotics like 9,10-phenanthrenequinone in vitro. In human tissues, AKR1E2 is predominantly expressed in the upper intestinal regions (duodenum and jejunum) relative to the liver 1, distinguishing its distribution from AKR1C isoforms. The protein exhibits age-related stability with strong correlations in abundance with AKR1A1 (r = 0.91) 2. Clinically, AKR1E2 has been identified as a candidate gene in recessive pediatric cataract, with a homozygous mutation identified in one consanguineous family presenting with nonsyndromic disease 3. Additionally, differential AKR1E2 methylation patterns in peripheral blood have emerged as potential epigenetic biomarkers for predicting radiation-induced genitourinary and gastrointestinal toxicity in prostate cancer patients, with methylation signatures showing strong discriminatory accuracy (AUC = 0.98) 4. These findings suggest AKR1E2's involvement extends beyond routine xenobiotic metabolism to disease pathogenesis and treatment response prediction.